Related Experiment Video
Updated: Aug 9, 2026
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
Alpha-fetoprotein (AFP) levels in normal children
1Department of Pediatric Surgery, Ishikawa Prefectural Central Hospital, Japan.
Insights
This study refines normal serum alpha-fetoprotein (AFP) ranges for infants, creating a more precise graph to reduce false positives in childhood tumor marker testing.
Area of Science:
- Pediatric Oncology
- Biochemistry
- Clinical Chemistry
Background:
- Alpha-fetoprotein (AFP) is a critical tumor marker for diagnosing childhood cancers like yolk sac tumors and hepatoblastoma.
- Existing reference graphs for infant serum AFP levels, such as Tsuchida et al.'s, guide clinical evaluation.
- Accurate AFP level assessment is crucial for early and reliable diagnosis in pediatric oncology.
Observation:
- Serum AFP levels were measured using immunoradiometric assay in 163 healthy infants under two years of age.
- A new, more precise graph of normal serum AFP ranges was generated based on these measurements.
- The newly established normal range was found to be slightly wider than previously published ranges.
Findings:
- The refined normal range for infant serum AFP levels is more precise than existing graphs.
- Utilizing the new graph is expected to decrease the number of false-positive results in AFP testing.
- Understanding AFP half-lives in infancy aids in interpreting ambiguous AFP levels.
Implications:
- This study provides an improved tool for accurate AFP interpretation in early infancy.
- Reduced false positives can lead to more efficient and less stressful diagnostic pathways for children.
- The findings support enhanced diagnostic accuracy for pediatric tumors utilizing AFP as a biomarker.
Abstract:
Alpha-fetoprotein (AFP) is an important tumor marker for yolk sac tumor and hepatoblastoma in childhood. We have been using the graph of the normal range of serum AFP made by Tsuchida et al, when we evaluate the serum AFP levels in early infancy. We measured the serum AFP levels by an immunoradiometric assay in 163 normal infants under 2 years of age, in order to make a more precise graph. Our normal range was a little wider than that of Tsuchida et al. According to our graph, false-positive cases would be fewer. Referring to the half-lives of serum AFP levels in normal infancy is also useful, when it is difficult to evaluate the AFP level.
